Comparing endoscopic mucosal resection with endoscopic submucosal dissection in colorectal adenoma and tumors: Meta-analysis and system review

Abstract

Aims

This study aimed to evaluate the safety, efficacy, and long-term outcomes of endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) for treating colorectal adenomas and tumors.

Methods

A systematic literature review was conducted using databases including PubMed, Web of Science, and Embase. Parameters such as number of patients or lesions, histological diagnosis, lesion size, surgery time, en-bloc resection, R0 resection, severe postoperative complications, and local recurrence were extracted and pooled for analysis.

Results

A total of 12 retrospective studies involving 1289 patients and 1850 lesions were included in the analysis. EMR was found to have a shorter operation time by 53.6 minutes (95% CI: 51.3, 55.9, P<0.001) and fewer incidences of severe postoperative complications such as perforation and delayed bleeding (OR = 0.40, 95%CI: 0.23, 0.71, P<0.001). On the other hand, ESD had higher rates of en-bloc resection (OR = 0.15, 95%CI: 0.07, 0.30, P<0.001) and R0 resection (OR = 0.32, 95%CI: 0.16, 0.65, P<0.001). Recurrence after EMR was found to be significantly higher than that after ESD surgery (OR = 5.88, 95%CI: 2.15, 16.07, P = 0.037).

Conclusions

The study suggests that the choice of surgical method may have a greater impact on recurrence compared to the pathological type, and that ESD may be more suitable for the treatment of malignant lesions despite its higher rates of severe postoperative complications and longer operation time.

1. Introduction

Cancer is a growing concern globally, and its incidence and mortality rates are rapidly increasing. Colorectal cancer (CRC) was estimated to account for around 10% of all new cancer cases in 2018, totaling around 1.8 million cases [1]. Additionally, CRC related deaths were projected to account for about 9% of cancer related deaths, totaling around 860,000 deaths worldwide. The incidence of colon and rectal cancer is predicted to increase significantly by 2030, especially among younger age groups. The incidence rate is expected to increase by 90.0% and 124.2% among patients aged 20 to 34 for colon and rectal cancer respectively, and by 27.7% and 46.0% among patients aged 35 to 49 [2]. These projections highlight the urgent need for effective screening and treatment of CRC.

It is important to detect CRC early to increase patient survival rates, and screening tests such as colonoscopies have proven to be effective in detecting and preventing CRC. Colonscopic removal of adenomatous polyps can significantly decrease the risk of CRC [3]. In addition, many guidelines recommend endoscopic resection as an effective treatment for colo-rectal lesions, including different resection methods [4–6]. These approaches have proven to be beneficial in reducing morbidity and mortality rates associated with CRC.

Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) are minimally invasive and effective techniques for the treatment of precancerous lesions and early stages of CRC. These procedures are widely accepted in medical practice and have shown promising results in treating various types of neoplasia. However, the choice of the procedure depends on various factors such as the size, location, and nature of the lesion, as well as the patient’s overall health and medical history.

EMR is a highly effective and minimally invasive technique used to remove precancerous lesions that are less than 2 cm in size in an en-bloc fashion [7]. Utilizing underwater EMR has shown to produce better outcomes in terms of en-bloc and R0 resections and procedure time, particularly for lesions that are within the range of 30–40 mm in colorectal polyps, when compared with conventional EMR [8]. However, it should be noted that EMR is not without its limitations, as the piecemeal resection method is associated with high recurrence rates.

Compared with EMR, ESD achieved a higher R0 resection rate but more time consuming [9]. Moreover, ESD is more effective for early CRC and precancerous lesions, with higher en-bloc resection, higher R0 resection rate and lower local recurrence [9–11]. However, ESD had a higher risk for complications such as perforation and bleeding, while its hospitalization costs were higher, and endoscopic operation was technically demanding and more time consuming [9, 12].

Considering the strengths and weaknesses of both EMR and ESD, there is currently no definitive consensus on the ideal endoscopic therapy for colorectal adenoma and tumor. While previous Meta-analysis studies have been conducted [13–16], they suffer from certain limitations, including the inclusion of conference abstracts, the absence of Chinese literature, and outdated data due to the publication of new articles. Thus, the present study aims to comprehensively analyze and compare the effectiveness and safety of EMR and ESD as treatments for colorectal adenoma and tumor.

2. Materials and methods

2.1. PICO statement

The PICO statement was following:

* P-patient, problem or population: Patients undergoing endoscopic surgery (EMR or ESD) for colorectal adenomas or cancers.

* I-intervention or exposure: The endoscopic surgery (EMR & ESD).

* C-comparison, control or comparator: Comparison of the safety and efficiency of the two endoscopic procedures, and comparison of patients’ prognosis undergoing different endoscopic procedures.

* O-outcome: The primary outcome was the odds ratio (OR) of EMR as a risk factor and ESD as a contrast for the recurrence, the complication and successful excision of the lesion. The secondary outcome was mean differences between EMR and ESD group in terms of surgery time and lesion size.

2.2. Search strategy

Our aim was to identify all studies evaluating the difference between EMR and ESD measured by safety, surgical excision efficiency and long-term outcome of the patients. In accordance with the preferred reporting items for systematic reviews and Meta-analyses (PRISMA) guidelines, we searched published studies from PubMed, Web of Science and Embase from inception to September 12, 2022. We included in our analysis only studies that were published in full text or accepted for publication in indexed journals.

We identified all pertinent literature that were associated with endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD), colorectal cancer (CRC) and colorectal adenomas (CRA). We used (("Colorectal Adenomas") OR (("Colorectal tumors") OR ((lst) OR ("laterally spreading tumor")))) AND (((EMR) OR ("Endoscopic mucosal resection")) OR (("Endoscopic mucosal dissection") OR (ESD))) as the retrieval strategy. No additional retrieval restrictions were set to achieve higher recall. We also hand-searched the reference sections of previous Meta-analyses for relevant articles. The search was performed by two authors (N.W and XH.L) until no new records could be found.

2.3. Inclusion and exclusion criteria

Studies were identified based on predefined inclusion criteria:

a) the study was designed as a case-control, cohort study, cross-sectional study or clinical trail; b) the study declared clear diagnosis criteria with colorectal adenomas OR colorectal tumors OR laterally spreading tumor; c) the study compared the EMR and ESD and had accurate digitized results.

Studies were excluded based on the criteria:

a) the study type was review, Meta-analyses, comments, letters, case reports, non-human studies or meeting abstract; b) duplicate literature would be excluded; c) small sample research (total sample < 30); d) articles that cannot be found in full text would also be rejected.

We extracted the following data from each eligible article:

a) basic information: article title, name of the first author, publication year, country, study design; b) Study related data (numbers were recorded according to two different endoscopic procedures): patient number, age, the proportion of genders, lesion size, surgery time, number of en-bloc resection, number of R0 resection, number of severe postoperative complications (perforation, bleeding and so on), and number of tumor recurrence.

The records management was performed by two authors (N.W. and XH.L.). Conflicts regarding the inclusion or exclusion of articles were resolved by consensus with a third investigator (T.B.). The software Endnote X9 was used.

2.4. Risk of bias assessment

We predicted that the types of literature studies to be included would include non-randomized controlled trials and retrospective analysis, so we chosen the evaluation tools of non-randomized controlled trials, which is more rigorous. The Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) tool, which was recommended by the Cochrane Handbook for Systematic Reviews of Interventions to assess the risk of bias in a non-randomized study, was adopted [17, 18]. Non RCT studies were judged for the following seven domains: confounding bias, selection bias, bias in classification of interventions, bias in deviation from intended interventions, bias due to missing data, bias in measurement of outcome and bias in selection of the reported results. All risk of bias assessments were conducted by two reviewers (N.W. & XH.L.). Disagreements were resolved by recruiting a third author (T.B.) to attain consensus.

Studies were not excluded a prior based on quality assessment.

2.5. Data extraction

The following data were collected: basic information (title, author, date of publication), sample size, surgical lesion size, surgery time, number of en-bloc & R0 resection, number of severe postoperative complications and number of recurrence for different surgery (ESD or EMR).

In this work, postoperative perforation and delayed bleeding were defined as the serious postoperative complication and the total number of the two occurrences is added. Clinically, there are some derivations of EMR and ESD such as EPMR, EMR-P, CSI-EMR, hybrid ESD, ESD-S and so on. Considering that they were all performed on the basis of EMR or ESD, they would not be separately classified in our study, but included in the EMR or ESD category.

2.6. Data synthesis and meta-analysis

In this Meta-analysis, all statistical analyses were performed with STATA 14.0 (Stata Corporation, Texas, USA). Data from selected studies were extracted into 2×2 tables. Relative risk/odds ratio and 95% confidence intervals (95% CI) were calculated, and effect size (weighted mean difference) Meta-analysis was performed. The mean differences, as well as 95% confidence, intervals between EMR and ESD group in terms of surgery time and lesion size were also pooled. The heterogeneity among all the included studies was assessed using I².

In consideration of that the clinical size of the lesion may affect the operation time and postoperative complications, and the pathological nature of the lesion may affect the recurrence of the patient after surgery, Meta-regression and baseline correction based on Trowman method were performed [19, 20]. Both fixed effect model and random-effect model were applied for Meta-analysis.

Publication bias was assessed by using R-based Robvis software package introduced by the National Institute for Health Research (NIHR) [21].

The ethics approval was not required for the Meta-analysis since this study used only the data from already published studies and did not have patient personal information.

3. Results

3.1. Articles selection

We retrieved a total of 2,117 records, with 1,061, 380, and 676 records from Embase, PubMed, and Web of Science, respectively. After removing duplicates, we were left with 1,625 records. We screened the abstracts and found that 1,180 records were unrelated to the topic and 412 records did not meet the inclusion criteria for literature type. After the preliminary examination, only 33 records passed. We also found seventeen meeting abstracts, as well as one Korean article which could not be included. Besides, we excluded two articles which were unrelated to our topic, and one article which only had an abstract. After reading the full text, we finally included 12 articles in our work [23–34]. Our procedure is summarized in a preferred reporting item for systematic review and meta-analysis flow diagram (Fig 1).

[Figure omitted. See PDF.]

3.2. Methodology quality assessment and date extraction

The quality assessments of the included trials by using ROBINS-I tool were summarized in Table 1 and Fig 2. Most of literature was not clinical trials, so using this evaluation tool was somewhat harsh for most of the literature included. However, this evaluation tool more clearly showed the possible bias of each study, so it was still used.

[Figure omitted. See PDF.]

[Figure omitted. See PDF.]

After completing the assessment, the relevant data of all twelve articles were extracted, as shown in the Table 2.

[Figure omitted. See PDF.]

3.3. Merging and meta-analysis

All the above literatures with purposeful effect values were included in the Meta-analysis, and the effect values were pooled, respectively. EMR was used as the intervention group and ESD was used as the control group.

3.3.1. Lesion size and surgery time.

Clinically, doctors may prefer to choose EMR surgery for small lesions. The study reached similar conclusions that the lesions targeted by EMR tended to be smaller than those treated by ESD (Fig 3a). The tumor size of EMR was 11.0 [95%CI(10.8, 11.2)] millimeters smaller than that of ESD on average.

[Figure omitted. See PDF.]

a. Meta-analysis of tumor dimension(mm) difference between EMR and ESD. b. Meta-analysis of surgery time (EMR vs ESD).

EMR is considered to have a shorter operating time because of its simplicity. It prove that the operation time of EMR was 53.6 [95%CI(51.3, 55.9)] minutes shorter than that of ESD on average (Fig 3b).

Could the difference in lesion size explain the difference in surgical time? We used Meta-regression analyses (Trowman method) to include tumor size as a co-variate and found that the operation time of EMR was still 37.6 minutes shorter than that of ESD on average (P = 0.001) (S1 Table).

3.3.2. Histological diagnosis.

The pathological characteristics of the lesion often greatly affect the physical properties (stiffness, degree of edge smoothness and so on) of the lesion and the prognosis of the patient after resection (recurrence). Physical properties may affect surgical resection, and malignant lesions may predict a poor prognosis.

In this work, we plotted the number of adenomas and cancers (including carcinoma in situ) treated by EMR, and the number of adenomas and cancers (including carcinoma in situ) treated by MR In a four-grid table, and calculated the OR value. So a higher OR in a given study meant a higher proportion of adenomas in subjects underwent EMR and a higher proportion of cancer in subjects underwent ESD.

We demonstrated that researchers would choose ESD more for malignant lesions (Fig 4), this probably because the difference between ESD and EMR surgical methods. The pooled OR for histological diagnosis were 1.68 [95%CI(1.20, 2.17)] for random effect model and 1.66 [95%CI(1.22, 2.10)] for fixed effect model. I² for random effect model was 9.4% and P value was less than 0.001.

[Figure omitted. See PDF.]

3.3.3. En-bloc resection and R0 resection.

En-bloc resection and R0 resection often predict surgical success and a relatively good prognosis [34]. In our work, we found that EMR had fewer en-bloc resection and R0 resection than ESD. The pooled OR for en-bloc resection were 0.15 [95%CI(0.07, 0.30)] for random effect model and 0.14 [95%CI(0.11, 0.18)] for fixed effect model (Fig 5a). I² for random effect model was 83.9% and P value was less than 0.001. At the same time, the pooled OR for R0 resection were 0.32 [95%CI(0.16, 0.65)] for random effect model and 0.28 [95%CI(0.22, 0.35)] for fixed effect model (Fig 5b). I² for random effect model was 87.6% and P value was less than 0.001. So ESD can achieve more en-bloc resection and R0 resection.

[Figure omitted. See PDF.]

a. Meta-analysis of en-bloc resection (EMR vs ESD). b. Meta-analysis of R0 resection (EMR vs ESD).

3.3.4. Severe postoperative complications.

In this study, postoperative perforation and delayed bleeding were counted as serious postoperative complications, and the number of times they occur were added up to get the number of postoperative complications. As Fig 6, the diamond was on the left of the vertical line and did not intersect with the line (OR = 0.40 [95%CI(0.23, 0.71)] for random effect model and OR = 0.42 [95%CI(0.31, 0.57)] for fixed effect model). I² for random effect model was 58.3% and P value was 0.006. EMR had fewer severe postoperative complications than ESD. The severe postoperative complication rates after EMR and ESD were about 3%-5% and about 7%-10%, respectively (S1a and S1b Fig).

[Figure omitted. See PDF.]

3.3.5. Recurrence.

Whether there will be a recurrence of adenoma and adenocarcinoma after endoscopic resection is a concern. So, we drew a forest map to explore the question of which endoscopic procedure would reduce recurrence (Fig 7a). One article was excluded because the number of recurrences in both ESD and EMR were zero. We found that the diamond was on the right of the vertical line and did not intersect with the line (OR = 5.88 [95%CI(2.15, 16.07)] for random effect model and OR = 6.39 [95%CI(3.82, 10.68)] for fixed effect model). I² for random effect model was 57.7% and P value was 0.037. This meant the value of OR was statistically significant. Further, this meant that patients who underwent EMR were more likely to have a recurrence than those who underwent ESD.

[Figure omitted. See PDF.]

a. Meta-analysis of recurrence after EMR and ESD. b. Recurrence rate after EMR. c. Recurrence rate after ESD.

The recurrence rate after EMR and ESD were taken as the effective value respectively (Fig 7b and 7c). The average recurrence rates were obtained as follow: about 14–16% for EMR and about 1–2% for ESD.

Using regression analysis, with tumor size as a co-variate, a potential linear relationship between tumor size and recurrence was found, although the results showed no significance (P = 0.291 & P = 0.147 for EMR and ESD, respectively) (S2a and 2b Fig).

Usually, malignant lesions are associated with a poorer prognosis than benign ones. The results showed that the ESD group had a higher percentage of malignant lesions but a lower recurrence rate than EMR. To further confirm the relationship between the lesion type and recurrence, the Meta-regression analysis was adopted (this OR as a co-variate and OR of EMR vs ESD for recurrence was used as the dependent variable). We found this regression meaningless (P = 0.594), and even the number of tau² increased from 0.8016 to 1.237. This may mean that pathological type has a weaker effect on prognosis compared with surgical method.

4. Discussion

This Meta-analysis is the latest comparison of clinical outcomes between ESD and EMR in the treatment of colorectal tumors. A total of 12 articles with 3139 lesions were included in the analysis. The findings indicate that ESD was more effective than EMR in en-bloc resection rate and R0 resection, with EMR showing lower rates in both. Additionally, the local recurrence rate of EMR was higher than that of ESD. Further analysis revealed that local recurrence was affected by the choice of endoscopic resection method, rather than the postoperative pathological type. EMR had fewer complications, such as delayed bleeding and perforation, compared to ESD. On the other hand, ESD was more time-consuming and was mainly used for larger tumors.

Due to insufficient data, this paper did not conduct separate analyses on ESD and EMR surgery for certain important types of benign and malignant intestinal tumors, such as Colorectal laterally spreading tumors (LSTs) and Neuroendocrine tumors (NETs).

LSTs are flat lesions that grow laterally along the intestinal wall, with a diameter greater than 10 mm [35]. Due to their high risk of malignancy, LSTs are considered pre-cancerous lesions of CRC [36]. LSTs can be subclassified into granular types (LST-G), which have nodular surfaces, and non-granular types (LST-NG), which have smooth surfaces [37]. Early diagnosis and treatment are therefore crucial in preventing the progression of this disease. As LSTs grow laterally along the intestinal wall, they typically have a lower risk of submucosal invasion, making EMR and ESD the preferred initial treatment methods [38].

However, clinical research showed that LST-NG had a higher proportion of submucosal invasive lesions. Therefore, treatment should take into consideration LST subtypes and diameter, as well as the quality of life and prognosis of patients [39]. For larger size colorectal LSTs, with nodular mixed subtype, cancerous pit pattern, or early adenocarcinoma, en bloc or curative resection is recommended. ESD is a preferred treatment method [27, 31]. For lesions with a diameter greater than 20mm, EMR cannot achieve en bloc resection, which may result in local residual lesions or recurrence [27]. However, recent studies have shown that EMR is a safe and effective operation for LSTs larger than 4cm, and its effectiveness is not inferior to that of ESD [40]. In earlier research, EMR was considered a first-line treatment for LSTs, with a low risk of submucosal invasion [38]. For LSTs, the en-bloc resection rate of ESD and EMR were 96% and 93.7%, respectively, and the corresponding pathological R0 resection rates were 90.1% and 82.8% [28].

NETs are an uncommon type of tumor that originates from neuroendocrine cells, with the gastrointestinal tract and pancreas being the most common sites. In particular, rectal NETs account for approximately one-third of all gastrointestinal NETs [41, 42]. According to the mitotic count and the Ki-67 index, rectal NETs (≤1cm) are usually benign lesions [43]. However, as the size of the rectal NET increases, the risk of both lymph node and distant organ metastasis significantly increases [44]. In cases without vascular invasion, muscular invasion or lymph node metastasis, international guidelines recommend endoscopic resection for rectal NETs with a diameter of ≤1cm [45, 46]. Nonetheless, further investigation is still required to establish the efficacy of endoscopic treatment for rectal NETs. Recently, improved EMR has been shown to produce clinical outcomes that are as reliable as those achieved by ESD [30, 47].

A clinical study revealed that the en-bloc resection rate and histologically complete resection rate of rectal NETs treated with EMR were 99% and 72–74%, respectively; it was further considered that histologically complete resection might be related to tumor size, but not to endoscopic therapy [48]. However, our opinion was inconsistent regarding outcomes of endoscopic therapy. The Meta-analysis revealed that endoscopic therapy was closely related to local recurrence. The local recurrence rate of ESD was lower than that of EMR. We speculated that as long as the lesions did not invade the submucosa, the rate of en-bloc resection and local recurrence will gradually decrease with the improvement of endoscopic treatment. For skilled endoscopist, the size of the tumor may affect the operation time or postoperative complications. The complete resection rate of ESD was higher than that of EMR, which comparable to transanal endoscopic microsurgery [49]. Underwater EMR was superior to ESD in operation time, hospitalization time, operation cost, postoperative discomfort [50]. EMR with a ligation band device was more favorable for small rectal NETs (<10mm) with respect to clinical outcomes, procedure time, and technical difficulties [51]. Endoscopic resection was an effective treatment for small rectal NETs, while it still had a highly prevalent lymphovascular invasion in minute rectal NETs [52]. The findings of this Meta-analysis showed that ESD had a higher en bloc resection rate and R0 resection rate. Combined with the potential metastasis risk of rectal NETs, ESD may be the first choice and the optimal therapy for endoscopic resection.

Endoscopic resection is a minimally invasive treatment that can be used to treat early gastrointestinal cancer, such as esophageal cancer, gastric cancer, and colorectal cancer. It is important to achieve en-bloc and histologically complete resection during endoscopic treatment for a suspected or confirmed early colorectal cancer, according to the Clinical Practice Guideline [53].

EMR is an effective method for removing colorectal lesions that are smaller than 20 mm [54]. However, for larger lesions, piecemeal EMR may result in lower-quality and less reliable histopathologic findings, with higher rates of local recurrence and lower en-bloc resection rates [55]. In cases where colorectal lesions are highly suspected of being cancerous and limited to submucosal invasion, endoscopic submucosal dissection (ESD) may be considered for treatment [56]. ESD is widely considered a curative treatment for early colorectal cancer, as it achieves high rates of en-bloc resection and positive long-term outcomes for patients [57]. Compared to laparoscopic-assisted colorectal surgery, ESD produces lower complication rates and more favorable en-bloc and curative resection rates [58].

While ESD has a higher risk of delayed bleeding and perforation compared to EMR, these risks can be managed with certain precautions. Firstly, it is recommended that ESD be performed by experienced endoscopists. During the ESD procedure, high-frequency electrocoagulation can be used to stop bleeding at small vessels that are suspected of bleeding. Any bleeding points can also be identified and treated with high-frequency electrocoagulation after being clamped by hot forceps. In case of intraoperative perforation, metal clips can be applied to clamp the suspected or perforated sites for quick resolution of the issue.

One of the strengths of this Meta-analysis is the inclusion of a larger number of studies, including those from Chinese literature, which provides valuable insights from the latest clinical experience. Additionally, we used the GRADE tool to assess the quality of non-randomized controlled clinical trials, ensuring a more rigorous evaluation of the data. The heterogeneity of this Meta-analysis was only 60%, indicating a high level of consistency among the findings from each individual study. Our study explored various factors such as recurrence rate, en-bloc resection rate, R0 resection rate, operation time, and postoperative complications, which helped to explain the heterogeneity of results. Furthermore, we found that the operation mode had a significant impact on the recurrence rate, providing important information for improving treatment outcomes.

It is important to acknowledge that our research had several limitations. Firstly, there were differences in the lesion location in the selected literature, as the retrieval strategy used "colorectal," which may have excluded some rectal tumors. However, we tried to manually retrieve relevant studies to minimize this potential bias. Secondly, there were differences in the research design, inclusion criteria, and endoscopist’s experience in diagnosing and removing colorectal tumors among the different studies, which was reflected in the high heterogeneity index. Lastly, the included studies were not all randomized, which may have weakened the evidence level of this Meta-analysis to some extent. It is important to consider these limitations when interpreting our findings.

5. Conclusions

Based on the findings of this Meta-analysis, it can be concluded that both EMR and ESD are viable options for the endoscopic treatment of colorectal tumors. However, ESD appears to have noticeable advantages over EMR in terms of en-bloc resection rate, R0 resection rate, and recurrence rate. Therefore, it is recommended to use ESD for the endoscopic treatment of colorectal tumors, if feasible. Nevertheless, it is important to note that more high-quality randomized controlled clinical trials are needed to further investigate the effectiveness of ESD in the treatment of colorectal cancer. These studies will help solidify the evidence base and potentially refine current treatment guidelines.

Supporting information

S1 Fig.

a. Complication rate after EMR. b. Complication rate after ESD.

https://doi.org/10.1371/journal.pone.0291916.s001

(ZIP)

S2 Fig.

a. Meta-regression analysis for recurrence rate of EMR, tumor size as co-variate. b. Meta-regression analysis for recurrence rate of ESD, tumor size as co-variate.

https://doi.org/10.1371/journal.pone.0291916.s002

(ZIP)

S1 Table. Result of meta regression analyses (Trowman method) to include tumor size as a co-variate and surgery time (EMR vs ESD) as the dependent variable.

https://doi.org/10.1371/journal.pone.0291916.s003

(DOCX)

S1 Checklist. The meta-analysis was not registered and there was no protocol was prepared.

https://doi.org/10.1371/journal.pone.0291916.s004

(DOCX)

Citation: Wang N, Shu L, Liu S, Yang L, Bai T, Shi Z, et al. (2023) Comparing endoscopic mucosal resection with endoscopic submucosal dissection in colorectal adenoma and tumors: Meta-analysis and system review. PLoS ONE 18(9): e0291916. https://doi.org/10.1371/journal.pone.0291916

About the Authors:

Nian Wang

Contributed equally to this work with: Nian Wang, Lei Shu

Roles: Data curation, Writing – original draft

Affiliation: Division of Gastroenterology, Wuhan No. 1 Hospital, Wuhan, China

Lei Shu

Contributed equally to this work with: Nian Wang, Lei Shu

Roles: Data curation, Writing – original draft

Affiliation: Division of Gastroenterology, Wuhan No. 1 Hospital, Wuhan, China

Song Liu

Roles: Validation, Writing – review & editing

Affiliation: Division of Gastroenterology, Wuhan No. 1 Hospital, Wuhan, China

Lin Yang

Roles: Data curation, Validation

Affiliation: Division of Gastroenterology, Wuhan No. 1 Hospital, Wuhan, China

Tao Bai

Roles: Project administration

Affiliation: Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Zhaohong Shi

Roles: Investigation, Writing – review & editing

E-mail: [email protected] (XL); [email protected] (ZS)

Affiliation: Division of Gastroenterology, Wuhan No. 1 Hospital, Wuhan, China

Xinghuang Liu

Roles: Conceptualization, Methodology

E-mail: [email protected] (XL); [email protected] (ZS)

Affiliation: Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

ORICD: https://orcid.org/0000-0001-9992-6230

References

1. Bray Freddie, Ferlay Jacques, Soerjomataram Isabelle, Siegel Rebecca L, Torre Lindsey A, Jemal Ahmedin. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68, 394–424, pmid:30207593

2. Bailey Christina E, Hu Chung-Yuan, You Y Nancy, Bednarski Brian K, Rodriguez-Bigas Miguel A, Skibber John M, et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975–2010. JAMA Surg 150, 17–22, pmid:25372703

3. Zauber Ann G, Winawer Sidney J, O’Brien Michael J, Lansdorp-Vogelaar Iris, van Ballegooijen Marjolein, Hankey Benjamin F, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 366, 687–696, pmid:22356322

4. Tanaka Shinji, Kashida Hiroshi, Saito Yutaka, Yahagi Naohisa, Yamano Hiroo, Saito Shoichi, et al. Japan Gastroenterological Endoscopy Society guidelines for colorectal endoscopic submucosal dissection/endoscopic mucosal resection. Dig Endosc 32, 219–239, pmid:31566804

5. Uraoka Toshio, Takizawa Kohei, Tanaka Shinji, Kashida Hiroshi, Saito Yutaka, Yahagi Naohisa, et al. Guidelines for Colorectal Cold Polypectomy (supplement to "Guidelines for Colorectal Endoscopic Submucosal Dissection/Endoscopic Mucosal Resection"). Dig Endosc 34, 668–675, pmid:35113465

6. Saito Yutaka, Yamano Hiro-O. Indications for endoscopic resection of colorectal polyps and surveillance guidelines. Dig Endosc 22 Suppl 1, S38–42, pmid:20590770

7. Ning Bo, Abdelfatah Mohamed M, Othman Mohamed O. Endoscopic submucosal dissection and endoscopic mucosal resection for early stage esophageal cancer. Ann Cardiothorac Surg 6, 88–98, pmid:28446997

8. Nagl Sandra, Ebigbo Alanna, Goelder Stefan Karl, Roemmele Christoph, Neuhaus Lukas, Weber Tobias, et al. Underwater vs Conventional Endoscopic Mucosal Resection of Large Sessile or Flat Colorectal Polyps: A Prospective Randomized Controlled Trial. Gastroenterology 161, 1460–1474.e1461, pmid:34371000

9. Terheggen Grischa, Horn Eva Maria, Vieth Michael, Gabbert Helmut, Enderle Markus, Neugebauer Alexander, et al. A randomised trial of endoscopic submucosal dissection versus endoscopic mucosal resection for early Barrett’s neoplasia. Gut 66, 783–793, pmid:26801885

10. Yong Jie Ning, Lim Xiong Chang, Nistala Kameswara Rishi Yeshayahu, Lim Lincoln Kai En, Lim Grace En Hui, Quek Jingxuan, et al. Endoscopic submucosal dissection versus endoscopic mucosal resection for rectal carcinoid tumor. A meta-analysis and meta-regression with single-arm analysis. J Dig Dis 22, 562–571, pmid:34472210

11. Chao Guanqun, Zhang Shuo, Si Jianmin. Comparing endoscopic mucosal resection with endoscopic submucosal dissection: the different endoscopic techniques for colorectal tumors. J Surg Res 202, 204–215, pmid:27083968

12. Dumoulin Franz Ludwig, Hildenbrand Ralf. Endoscopic resection techniques for colorectal neoplasia: Current developments. World J Gastroenterol 25, 300–307, pmid:30686899

13. Lim Xiong Chang, Nistala Kameswara Rishi Yeshayahu, Ng Cheng Han, Lin Snow Yunni, Tan Darren Jun Hao, Ho Khek-Yu, et al. Endoscopic submucosal dissection vs endoscopic mucosal resection for colorectal polyps: A meta-analysis and meta-regression with single arm analysis. World J Gastroenterol 27, 3925–3939, pmid:34321855

14. Wang Jing, Zhang Xiao-Hua, Ge Jian, Yang Chong-Mei, Liu Ji-Yong, Zhao Shu-Lei, et al. Endoscopic submucosal dissection vs endoscopic mucosal resection for colorectal tumors: a meta-analysis. World J Gastroenterol 20, 8282–8287, pmid:25009404

15. Vaganov Yu E, Nagudov M A, Khomyakov E A, Achkasov S I. Endoscopic submucosal dissection versus endoscopic mucosal resection for colorectal tumors: a systematic review and meta-analysis. Khirurgiia (Mosk), 77–84, 34480459, pmid:34480459

16. Zhao Hong-Jing, Yin Jie, Ji Cui-Ying, Wang Xin, Wang Na. Endoscopic mucosal resection versus endoscopic submucosal dissection for colorectal laterally spreading tumors: a meta-analysis. Rev Esp Enferm Dig 112, 941–947, pmid:33207885

17. Sterne JAC, H. M., McAleenan A, Reeves BC, Higgins JPT. Assessing risk of bias in a non-randomized study. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane Chapter 25 (2022).

18. Sterne Jonathan Ac, Hernán Miguel A, Reeves Barnaby C, Savović Jelena, Berkman Nancy D, Viswanathan Meera,. et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016 Oct 12;355:i4919, pmid:27733354

19. Thompson Simon G, Higgins Julian P T. How should meta-regression analyses be undertaken and interpreted? Stat Med 21, 1559–1573, pmid:12111920

20. Friedrich Jan O, Adhikari Neill K J, Beyene Joseph. Ratio of geometric means to analyze continuous outcomes in meta-analysis: comparison to mean differences and ratio of arithmetic means using empiric data and simulation. Stat Med 31, 1857–1886, pmid:22438170

21. McGuinness Luke A, Higgins Julian P T. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods 12, 55–61, pmid:32336025

22. Saito Yutaka, Fukuzawa Masakatsu, Matsuda Takahisa, Fukunaga Shusei, Sakamoto Taku, Uraoka Toshio, et al. Clinical outcome of endoscopic submucosal dissection versus endoscopic mucosal resection of large colorectal tumors as determined by curative resection. Surg Endosc 24, 343–352, pmid:19517168

23. Kim Yun Jung, Kim Eun Soo, Cho Kwang Bum, Park Kyung Sik, Jang Byoung Kuk, Chung Woo Jin, et al. Comparison of clinical outcomes among different endoscopic resection methods for treating colorectal neoplasia. Dig Dis Sci 58, 1727–1736, pmid:23385636

24. Tajika Masahiro, Niwa Yasumasa, Bhatia Vikram, Kondo Shinya, Tanaka Tsutomu, Mizuno Nobumasa, et al. Comparison of endoscopic submucosal dissection and endoscopic mucosal resection for large colorectal tumors. Eur J Gastroenterol Hepatol 23, 1042–1049, pmid:21869682

25. Terasaki Motomi, Tanaka Shinji, Oka Shiro, Nakadoi Koichi, Takata Sayaka, Kanao Hiroyuki, et al. Clinical outcomes of endoscopic submucosal dissection and endoscopic mucosal resection for laterally spreading tumors larger than 20 mm. J Gastroenterol Hepatol 27, 734–740, pmid:22098630

26. Jiale Zou, Ningli Chai, Yaqi Zhai, Zantao Wang, Xiangyao Wang, Longsong Li et al. Endoscopic resection for colorectal laterally spreading tumors. Chin J Dig Endosc.2020;37(3).

27. Lee Eun-Jung, Lee Jae Bum, Lee Suk Hee, Youk Eui Gon. Endoscopic treatment of large colorectal tumors: comparison of endoscopic mucosal resection, endoscopic mucosal resection-precutting, and endoscopic submucosal dissection. Surg Endosc 26, 2220–2230, pmid:22278105

28. Li Yue, Zhang Yue, Chen Yao, Wang Yusi, Dou Lizhou, Wang Xianfei, et al. Long-term outcomes of endoscopic treatment for colorectal laterally spreading tumor: a large-scale multicenter retrospective study from China. Surg Endosc 35, 736–744, pmid:32076862

29. Kobayashi Nozomu, Yoshitake Naoto, Hirahara Yoshitaka, Konishi Jun, Saito Yutaka, Matsuda Takahisa, et al. Matched case-control study comparing endoscopic submucosal dissection and endoscopic mucosal resection for colorectal tumors. J Gastroenterol Hepatol 27, 728–733, pmid:22004124

30. Cheung Dae Young, Choi Soo Kyoung, Kim Hyung-Keun, Kim Sung Soo, Chae Hiun-Suk, Seo Kyung Jin, et al. Circumferential submucosal incision prior to endoscopic mucosal resection provides comparable clinical outcomes to submucosal dissection for well-differentiated neuroendocrine tumors of the rectum. Surg Endosc 29, 1500–1505, pmid:25277474

31. Jung Jin-Sung, Hong Ji-Yun, Oh Hyung-Hoon, Kweon Sun-Seog, Lee Jun, Kim Sang-Wook, et al. Clinical outcomes of endoscopic resection for colorectal laterally spreading tumors with advanced histology. Surg Endosc 33, 2562–2571, pmid:30350100

32. Toyonaga Takashi, Man-I Mariko, Morita Yoshinori, Sanuki Tsuyoshi, Yoshida Masaru, Kutsumi Hiromu, et al. The new resources of treatment for early stage colorectal tumors: EMR with small incision and simplified endoscopic submucosal dissection. Dig Endosc 21 Suppl 1, S31–37, pmid:19691730

33. Yongkang Cui, Shuang Li, Lixin Hou, Shu Li. Efficacy of Endoscopic Treatment in Patients With Colorectal Laterally Spreading Tumors. Chinese Journal of Gastroenterology 25, 167–170 (2020),

34. Patel Nisha, Patel Kinesh, Ashrafian Hutan, Athanasiou Thanos, Darzi Ara, Teare Julian, et al. Colorectal endoscopic submucosal dissection: Systematic review of mid-term clinical outcomes. Dig Endosc 28, 405–416, pmid:26710317

35. Kudo S. Endoscopic mucosal resection of flat and depressed types of early colorectal cancer. Endoscopy 25, 455–461, pmid:8261988

36. Sanduleanu Silvia, Siersema Peter D. Laterally spreading tumor through the magnifying glass: we only see what we know. Endoscopy 48, 421–423, pmid:27115921

37. Soetikno Roy, Friedland Shai, Kaltenbach Tonya, Chayama Kazuaki, Tanaka Shinji. Nonpolypoid (flat and depressed) colorectal neoplasms. Gastroenterology 130, 566–576; quiz 588–569, pmid:16472608

38. Saito Y, Fujii , Kondo H, Mukai H, Yokota T, Kozu T, et al. Endoscopic treatment for laterally spreading tumors in the colon. Endoscopy 33, 682–686, pmid:11490384

39. Horiuchi Yusuke, Chino Akiko, Matsuo Yasumasa, Kishihara Teruhito, Uragami Naoyuki, Fujimoto Yoshiya, et al. Diagnosis of laterally spreading tumors (LST) in the rectum and selection of treatment: characteristics of each of the subclassifications of LST in the rectum. Dig Endosc 25, 608–614, pmid:23369130

40. Ah Soune Philippe, Ménard Charles, Salah Ezzedine, Desjeux Ariadne, Grimaud Jean-Charles, Barthet Marc. Large endoscopic mucosal resection for colorectal tumors exceeding 4 cm. World J Gastroenterol 16, 588–595, pmid:20128027

41. Clift Ashley Kieran, Kidd Mark, Bodei Lisa, Toumpanakis Christos, Baum Richard P, Oberg Kjell, et al. Neuroendocrine Neoplasms of the Small Bowel and Pancreas. Neuroendocrinology 110, 444–476, pmid:31557758

42. Haider Mintallah, Al-Toubah Taymeyah, El-Haddad Ghassan, Strosberg Jonathan. Molecular Imaging and Therapy for Neuroendocrine Tumors. Curr Treat Options Oncol 20, 78, pmid:31468190

43. Kim Gwang-Un, Kim Kyung-Jo, Hong Seung-Mo, Yu Eun-Sil, Yang Dong-Hoon, Jung Kee Wook, et al. Clinical outcomes of rectal neuroendocrine tumors ≤ 10 mm following endoscopic resection. Endoscopy 45, 1018–1023, pmid:24288222

44. Chung Hye Gyo, Goh Myung Ji, Kim Eun Ran, Hong Sung Noh, Kim Tae Jun, Chang Dong Kyung, et al. Recurrence pattern and surveillance strategy for rectal neuroendocrine tumors after endoscopic resection. J Gastroenterol Hepatol 36, 968–973, pmid:32864790

45. de Mestier Louis, Cadiot Guillaume. Rectal neuroendocrine tumors: is it all on first sight? Endoscopy 53, 710–712, pmid:34167158

46. Gonzalez Raul S. Diagnosis and Management of Gastrointestinal Neuroendocrine Neoplasms. Surg Pathol Clin 13, 377–397, pmid:32773190

47. Zhou Xin, Xie Haiting, Xie Lingduo, Li Jing, Cao Weihua, Fu Wei. Endoscopic resection therapies for rectal neuroendocrine tumors: a systematic review and meta-analysis. J Gastroenterol Hepatol 29, 259–268, pmid:24118068

48. Kim Jihye, Kim Jee Hyun, Lee Joo Young, Chun Jaeyoung, Im Jong Pil, Kim Joo Sung. Clinical outcomes of endoscopic mucosal resection for rectal neuroendocrine tumor. BMC Gastroenterol 18, 77, pmid:29866049

49. Jeon Joon Han, Cheung Dae Young, Lee Seong Jin, Kim Hyun Jin, Kim Hye Kang, Cho Hyung Jun, et al. Endoscopic resection yields reliable outcomes for small rectal neuroendocrine tumors. Dig Endosc 26, 556–563, pmid:24447261

50. Shi Haitao, Wang Chuying, Wu Jie, Qin Bin, Jiang Jiong, Liu Na, et al. Underwater endoscopic mucosal resection for rectal neuroendocrine tumors (with videos): a single center retrospective study. BMC Gastroenterol 22, 276, pmid:35655173

51. Lim Hong Kyu, Lee Seong Jun, Baek Dong Hoon, Park Do Youn, Lee Bong Eun, Park Eun Young, et al. Resectability of Rectal Neuroendocrine Tumors Using Endoscopic Mucosal Resection with a Ligation Band Device and Endoscopic Submucosal Dissection. Gastroenterol Res Pract 2019, 8425157, pmid:31687016

52. Sekiguchi Masau, Sekine Shigeki, Sakamoto Taku, Otake Yosuke, Nakajima Takeshi, Matsuda Takahisa, et al. Excellent prognosis following endoscopic resection of patients with rectal neuroendocrine tumors despite the frequent presence of lymphovascular invasion. J Gastroenterol 50, 1184–1189, pmid:25936647

53. Park Chan Hyuk, Yang Dong-Hoon, Kim Jong Wook, Kim Jie-Hyun, Kim Ji Hyun, Min Yang Won, et al. Clinical Practice Guideline for Endoscopic Resection of Early Gastrointestinal Cancer. Clin Endosc 53, 142–166, pmid:32252507

54. Repici Alessandro, Pellicano Rinaldo, Strangio Giuseppe, Danese Silvio, Fagoonee Sharmila, Malesci Alberto. Endoscopic mucosal resection for early colorectal neoplasia: pathologic basis, procedures, and outcomes. Dis Colon Rectum 52, 1502–1515, pmid:19617768

55. Cao Y, Liao C, Tan A, Gao Y, Mo Z, Gao F. Meta-analysis of endoscopic submucosal dissection versus endoscopic mucosal resection for tumors of the gastrointestinal tract. Endoscopy 41, 751–757, pmid:19693750

56. Pimentel-Nunes Pedro, Dinis-Ribeiro Mário, Ponchon Thierry, Repici Alessandro, Vieth Michael, De Ceglie Antonella, et al. Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 47, 829–854, pmid:26317585

57. Shin Jongbeom, Kim Eun Ran, Jang Hyun Joo Baek Dong Hoon, Yang Dong-Hoon, Lee Bo-In, et al. Long-term prognosis of curative endoscopic submucosal dissection for early colorectal cancer according to submucosal invasion: a multicenter cohort study. BMC Gastroenterol 22, 417, pmid:36100888

58. Kiriyama S, Saito Y, Yamamoto S, Soetikno R, Matsuda T, Nakajima T, et al. Comparison of endoscopic submucosal dissection with laparoscopic-assisted colorectal surgery for early-stage colorectal cancer: a retrospective analysis. Endoscopy 44, 1024–1030, pmid:23012216